En savoir plus

    Philippe Langella is Research Director at INRAE and Head of the Laboratory of Commensals and Probiotics-Host Interactions (Micalis Institute). Since 1993, his team has developed new uses of LAB as live delivery vehicles to improve human health and has acquired a leadership position in the field of such recombinant LAB (recLAB). Since 2004, Philippe Langella is strongly involved in both commensals and probiotics domains to better understand the mechanisms of these bacteria and to enhance their use in human and animal health. His main goal is to gain a better understanding of the crosstalk between these resident and transiting bacteria and the host in order to unravel the mechanisms of their beneficial effects on human health. He’s more particularly studying anti-inflammatory effects of commensals and probiotics in murine models.

   Philippe Langella has authored 250 peer-reviewed international publications at the interface between microbiology and human health (WoK h-index 64). He’s co-inventor of 26 patents in the domain of the use of commensal and probiotic bacteria in health domain. He has participated in numerous national and European research projects and has strong research collaborations with several agro-food and pharmaceutical companies. He’s a referee for many international journals and consulting expert for several agro-food and pharmaceutical companies. Finally, he’s one of the co-founder of the biotech company Exeliom Biosciences.

Philippe Langella, can you tell us few words about you ?

   Yes, of course ! I started to work on genetics of lactic acid bacteria (LAB) in 1983. My most-achieved project concerns a new strategy to prevent and to fight against intestinal inflammatory pathologies using recLAB delivering the human antiprotease elafin (recLAB; Science Translational Medicine, 2012). In 2014, I have collaborated with Elena Verdu (McMaster, Hamilton, Canada) and we have shown the efficacy of elafin recLAB in her celiac disease model (American Journal of Gastroenterology, 2014). My laboratory is also leader in the use of recombinant probiotics to deliver molecules of health interest at the mucosal level and I recently patented such novel anti-inflammatory strains. I’m co-inventor of numerous patents in the domain of the use of commensal and probiotic bacteria in health domain. I’m also interested in studying anti-inflammatory effects of commensals and probiotics in murine models. In 2008, my laboratory has identified Faecalibacterium prausnitzii, the first anti-inflammatory commensal bacterium based on human clinical data (PNAS, 2008). In 2016, I have co-founded Exeliom Biosciences in order to use F. prausnitzii as a Live Biotherapeutics (LBPs). More recently, we have identified novel commensal bacteria producing metabolites able to protect mice in inflammation (Nature Medicine, 2016) and in metabolic syndrome (Cell Metabolism, 2018) models. Recently, we have shown the efficacy of these novel commensal bacteria in the same celiac disease model (Science Translational Medicine, 2020). I'am very Happy to take part in the CBL!

Thank you Philippe!